Posts

Posted on

BWF Partners with Creative to Add Holography To Badminton Live Streams with SXFI LIVE

Milpitas, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) — Badminton World Federation (BWF) has partnered with Creative Technology to enhance the fan experience of watching badminton matches by bringing the audience closer to the action through holographic audio.

Starting tomorrow at the HSBC BWF World Tour Finals in Bangkok, Thailand, live and delayed matches on BWF’s YouTube channel will be enhanced with SXFI LIVE. Making its debut as the latest iteration of the multiple award-winning Super X-Fi headphone holography, SXFI LIVE adds audio holography and recreates the soundstage of a premium multi-speaker system in a pair of normal headphones.

Processed in real time at the source of the live stream, fans will be able to enjoy the lifelike effects of Super X-Fi audio, regardless of the headphones they wear when watching the live streams on YouTube, and feel as though they are watching the matches live in the arena.


Bringing the Game Closer to the Fans


BWF Secretary General Thomas Lund said the progressive partnership was a positive step for badminton. “2020 was an unprecedented year in sport. The BWF has learned some valuable lessons about content curation in the absence of live events.

“As we begin 2021 with the possibility of some of our events hosted without live audiences, such as in Bangkok this week, we are delighted to partner with Creative to enhance the audio fan experience, even when virtual.

“We look forward to working with Creative and the clever SXFI LIVE technology going forward.”

Sim Wong Hoo, CEO of Creative, said: “We are thrilled to be partners with BWF in a first-of-its kind initiative. This is a win-win-win partnership – Creative brings its technology and products to a global sport and audience. BWF becomes the first sports body to incorporate ground breaking audio technology to its events. Over 700 million badminton fans can now enjoy lifelike badminton live streams through their headphones.

“By transforming the audio quality right from the source, we bring the best seat in the badminton arena, smashes, flicks and all, to the fans in the comfort of their own homes. This is as close to the real thing as it gets, short of the fans returning to the arena. Aside from creating the spatialization and improving the immersion, SXFI LIVE will let people hear more details from the matches, through an ultra-wide soundstage compared to regular audio.”


SXFI LIVE for all BWF Major Championships and BWF World Tour Finals

SXFI LIVE will be featured in all of BWF’s top-tier Major tournaments in 2021, including the TOTAL BWF Sudirman Cup, TOTAL BWF Thomas and Uber Cup Finals, BWF World Championships and HSBC BWF World Tour Finals. 

For more information, please visit https://www.creative.com/BWFSXFI.


About Creative


Creative is a worldwide leader in digital entertainment products. Famous for its Sound Blaster® sound cards and for driving the multimedia revolution – which established a user base of 400 million – Creative drives digital entertainment with cutting-edge audio solutions that include premium wireless speakers, wireless headphones, powerful audiophile-grade digital amplifiers and next-generation home-theatre systems. Aiming at the new mobile networked generation by bridging the worlds of the computer, smartphones, and tablets, Creative continues to reinvent the Sound Blaster, with its ground-breaking Sound Blaster Roar series and USB-audio class of products such as the Sound Blaster X7.

In 2016, Creative unveiled the X-Fi Sonic Carrier: a brand-new concept in hi-res audio and video delivery for home entertainment. This technology powerhouse dubbed ‘the soundbar of the gods’ personifies the Audio of Tomorrow.

In 2018, Creative launched an all-new game-changing technology for headphones called Super X-Fi® Headphone Holography. This technology uses computational audio to recreate the listening experience of a high-end multi-speaker system in a professional studio, and delivers the same expansive experience – with the same original depth, detail, realism, and spaciousness – in headphones. Super X-Fi further uses Artificial Intelligence to compute a custom audio profile based on a person’s unique anthropometry. Super X-Fi has won multiple accolades worldwide, including an unprecedented 23 awards at CES 2019-2020.

Visit

creative.com

Find out more about Super X-Fi Technology:

sxfi.com

Facebook:

facebook.com/CreativeLabs


About BWF


The Badminton World Federation (BWF) is the international governing body of the sport of badminton, recognised by the International Olympic Committee (IOC) and the International Paralympic Committee (IPC). It was originally the International Badminton Federation (IBF) which was founded on 5 July 1934, before being rechristened the Badminton World Federation in 2006.

The purpose and objectives of BWF include regulating, promoting, developing and popularising the sport of badminton throughout the world and organising, conducting and presenting international events at the highest level.

The BWF’s vision is to make badminton a leading global sport accessible to all – giving every child a chance to play for life. Its mission is to lead and inspire all stakeholders; to deliver entertainment through exciting events to drive fan experience; and to create innovative, impactful and sustainable development initiatives.

BWF has its headquarters in Kuala Lumpur, Malaysia, with 196 Member Associations worldwide.

Poul-Erik Høyer is the BWF President and Thomas Lund is the BWF Secretary General.

Websites:


www.bwfbadminton.com

 and www.bwfcorporate.com

Facebook:


https://www.facebook.com/bwfbadminton


# # #



Creative Press Contact
Edwin Ong 
Marketing Communications Manager
Mobile: +65 9795 7590
[email protected]


BWF Press Contact
Lloyd Green
Communications & Media Manager
Mobile: +60 19-384 0556

Dianne Pierre
Deputy Communications & Media Manager
Mobile: +44 7961 714540

[email protected]

Posted on

Decklar Resources Inc. Provides Update to Funding for Restart of Production at its Oza Oil Field

TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) — Decklar Resources Inc. (DKL-TSX Venture)(the “Company”) is pleased to provide an update to previously announced funding arrangements by its wholly-owned Nigeria-based subsidiary, Decklar Petroleum Limited, to develop the Oza Oil Field in Nigeria. When fully disbursed, these funds are expected to be sufficient to re-establish oil production and provide development funding for the Company’s Oza Oil Field. The details of the funding plans are included in the Company’s August 31, 2020 press release.


Update Regarding Funding Arrangements

The due diligence required to finalize the term debt arranged with a Nigerian bank and the trading subsidiary of a large multinational oil company active in Nigeria has progressed, and the final report by the independent technical consultant they contracted and based on review of reserve and production data and financial projections has been issued. The definitive loan documents are now being finalized and are anticipated to be issued by the end of the first week of February 2021. As previously announced, the remainder of the US$7,500,000 for the subscription agreement with San Leon Energy Plc remains in escrow and will be released upon satisfaction (or waiver) of the final conditions precedent contained in the agreement.


Update Regarding Oza Field Preparation

Well Site and drilling location preparation for the Oza-1 well re-entry and first horizontal development well have moved forward, and we are pleased to report have now been completed. The road to the well site location has been rebuilt and construction of a concrete drilling pad, concrete mud pit, buildings and related infrastructure have been completed. Long lead time items needed for the Oza-1 re-entry have been secured, and a drilling rig currently located near the field has been identified and contracted.

As previously reported, an export pipeline that ties the Oza Oil Field production into the Trans Niger Pipeline (TNP) and continues on to the Bonny Export Terminal, operated by Shell Production Development Company (SPDC) is already in place. Infrastructure also in place at the Oza Oil Field includes a lease automatic custody transfer (LACT) unit fiscal metering system, infield flow-lines, manifolds and a rental 6,000 barrel per day early production facility. These production and pipeline facilities ensure that oil tested from the Oza-1 well re-entry and early production will be immediately delivered and sold on an expedited basis.

For further information:

Duncan T. Blount
Chief Executive Officer     Telephone: +1 305 890 6516
Email: [email protected] 

David Halpin
VP Finance, Decklar Petroleum     Telephone: +1 403 816 3029
Email: [email protected]

Investor Relations: [email protected] 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Cautionary Language

Certain statements made and information contained herein constitute “forward-looking information” (within the meaning of applicable Canadian securities legislation). All statements in this news release, other than statements of historical facts, including statements with respect to the Company satisfying all outstanding conditions precedent in order to complete the transaction with San Leon are forward-looking statements. Such statements and information (together, “forward looking statements”) relate to future events or the Company’s future performance, business prospects or opportunities.

All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe” and similar expressions) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Company believes that the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. The Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws. These forward-looking statements involve risks and uncertainties relating to, among other things, changes in oil prices, results of exploration and development activities, uninsured risks, regulatory changes, defects in title, availability of materials and equipment, timeliness of government or other regulatory approvals, actual performance of facilities, availability of financing on reasonable terms, availability of third party service providers, equipment and processes relative to specifications and expectations and unanticipated environmental impacts on operations. Actual results may differ materially from those expressed or implied by such forward-looking statements.

The Company provides no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not assume the obligation to revise or update these forward-looking statements after the date of this document or to revise them to reflect the occurrence of future unanticipated events, except as may be required under applicable securities laws.



Posted on

Fentura Financial, Inc. Announces Quarterly Dividend

FENTON, Mich., Jan. 29, 2021 (GLOBE NEWSWIRE) — Fentura Financial, Inc. (OTCQX: FETM) has announced a regular dividend of $0.08 per share for shareholders of record as of February 8, 2021, and payable February 15, 2021.

About Fentura Financial, Inc. and The State Bank

Fentura Financial, Inc. is the holding company for The State Bank. It was formed in 1987 and is traded on the OTCQX exchange under the symbol FETM, and was recognized as one of the Top 50 performing stocks in 2018 and 2019 on that exchange.

The State Bank is a full-service, 5-Star Bauer Financial rated commercial, retail and trust bank headquartered in Fenton, Michigan. It currently operates 15 full-service branches in Genesee, Livingston, Oakland, Saginaw, and Shiawassee Counties and a loan production office in Saginaw County. The State Bank was ranked #22 by S&P Global in terms of 2019 performance for banks under $2 billion in assets. The State Bank’s commercial department provides a complete array of products including lines of credit, term loans, commercial mortgages, SBA loans and a full-suite of cash management products. The retail department offers personal checking, savings, time and IRA deposit accounts and a wide array of loan products including home equity, auto and personal loans. The residential loan department offers construction, purchase and refinance residential mortgage loans. The wealth management department offers a full-service suite of trust and portfolio management services. More information can be found at www.thestatebank.com or www.fentura.com.

Cautionary Statement:
This press release contains certain forward-looking statements that involve risks and uncertainties. Forward-looking statements include, but are not limited to, statements concerning future growth in earning assets and net income. Such statements are subject to certain risks and uncertainties which could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, economic, competitive, governmental and technological factors affecting the Company’s operations, markets, products, services, interest rates and fees for services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Contacts: Ronald L. Justice                 Aaron D. Wirsing
  President & CEO                 Chief Financial Officer
  Fentura Financial, Inc.                 Fentura Financial, Inc.
  810.714.3902                         810.714.3925
  [email protected]                 [email protected]



Posted on

Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction

Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study

European Commission decision on the Marketing Authorisation Application expected in April 2021

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that in response to Amarin’s Marketing Authorisation Application submission, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending that a marketing authorisation be granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA®.
        
The CHMP recommendation is now expected to be reviewed by the European Commission, which has the authority to approve medicines for marketing in the European Union. A decision by the European Commission is expected to take place within 67 days of the CHMP opinion.

“We thank the EMA for its thoughtful review of our application and concluding it in a timely manner despite the challenges imposed by COVID-19,” said Steven Ketchum, senior vice president, president of R&D and chief scientific officer of Amarin. “This positive CHMP opinion is a significant milestone for Amarin, taking us one step closer to making this important therapy available to millions of patients in the European Union at high risk of cardiovascular events such as heart attacks and strokes. We are dedicated to supporting a rethinking of cardiovascular disease risk reduction in Europe with further emphasis on preventative care.”

The CHMP opinion is based on over a decade of development and testing of icosapent ethyl, including data from the REDUCE-IT® cardiovascular outcomes study. REDUCE-IT evaluated more than 8,000 high risk patients who despite having their cholesterol levels well controlled by statin therapy remained at significant risk of heart attack, stroke, or other major adverse cardiovascular events (MACE), including death. As published, patients in the REDUCE-IT study had a median follow-up period of nearly five years. Results from this study, in which all patients remained treated by statins (and by other contemporary therapies) and where half the patients received icosapent ethyl and the other half received placebo, demonstrated a 25% relative risk reduction (p<0.001) in the first occurrence of MACE in the intent-to-treat patient population with use of icosapent ethyl (4 grams daily) compared with placebo.

Based on communications with the EMA we expect the indication language to be generally consistent with the following:

That marketing authorisation be granted to icosapent ethyl to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL), and

  • established cardiovascular disease, or
  • diabetes, and at least one other cardiovascular risk factor.

Ten years of market protection is expected to be granted in the European Union as part of a European Commission approval of the pending application. In addition, pending patent applications related to the REDUCE-IT study have the potential to extend exclusivity in Europe into 2039.

For more information about the CHMP announcement visit the EMA website (this link will take you to an external website) https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021 

About Amarin

Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

Promotion Disclaimer

This press release is intended for investor relations purposes. Icosapent ethyl is not approved for marketing or sale in the European Union and nothing in this press release is intended to promote such use.

Forward-Looking Statements

This press release contains forward-looking statements, including statements about expectation for further regulatory review, the expected timing thereof, anticipated label language, anticipated grants of regulatory exclusivity and the potential for patent issuances and protection. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties that may individually or together impact the matters herein and cause actual results, events and performance to differ materially from such forward looking statements. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: events that could impact future regulatory assessment by the European Commission, such as delays due to COVID-19 restrictions, later arising data or other information, events that could interfere with the grant or issuance of a patent, continued validity or enforceability of a patent; uncertainties associated with litigation generally and patent litigation specifically; Amarin’s ability generally to maintain adequate patent protection and successfully enforce patent claims against third parties; and uncertainties associated generally with research and development and regulatory submissions, reviews, action dates and approvals. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Amarin Contact Information


Investor Inquiries:


Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
[email protected] (investor inquiries)

Solebury Trout
[email protected]


US Media Inquiries:


Alina Kolomeyer
Communications
Amarin Corporation plc
In U.S.: +1 (908) 892-2028
[email protected] (media inquiries)


Europe Media Inquiries:


Liam English
Europe Communications
Amarin Corporation plc
+44 (0) 750 500 8787
[email protected] (media inquiries)



Posted on

Moore Kuehn, PLLC Encourages Investors of VYGR, TILE, or SWI to Contact Law Firm

PR Newswire

NEW YORK, Jan. 29, 2021 /PRNewswire/ — Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:


  • Voyager
     (NASDAQ: VYGR)

Voyager made misleading and false statements to the market. Voyager’s IND submission to the FDA for VY-HTT01 failed to include essential information in regard to chemistry, manufacturing and controls matters including product characterization and drug-device compatibility. Based on this failure, Voyager’s IND submission for VY-HTT01 was deficient. Voyager overstated the likelihood of the IND submission achieving FDA approval. Voyager’s public statements were materially misleading and false throughout the class period, based on these facts. Investors suffered damages when the market learned the truth.


  • Interface, Inc.
    (NASDAQ: TILE)

Interface issued misleading and/or false statements and/or failed to disclose information pertinent to investors. Interface is the subject of a press release distributed by the SEC on September 28, 2020. This SEC release, titled, “Interface and Two Former Executives Charged With Accounting and Disclosure Violations,” states that “[t]he SEC’s order against Interface, Inc. . . . finds that in multiple quarters in 2015 and 2016, the company made unsupported, manual accounting adjustments that were not compliant with GAAP.” On September 29, 2020, shares of Interface dropped in intraday trading.


  • SolarWinds Corp
    (NYSE: SWI)

Since mid-2020, SolarWinds Orion monitoring products had a vulnerability that allowed hackers to compromise the server upon which the products ran; SolarWinds’ update server had an easily accessible password of ‘solarwinds123′; consequently, SolarWinds’ customers, including, among others, the Federal Government, Microsoft, Cisco, and Nvidia, would be vulnerable to hacks; as a result, the Company would suffer significant reputational harm; and statements about SolarWinds’s business, operations and prospects were materially false and misleading.

If you own VYGR, TILE, or SWI please contact Fletcher Moore, Esq. by email at [email protected] or telephone at (212) 709-8245.  There is no cost to you.  Moore Kuehn is a New York-based law firm with attorneys representing investors and consumers. Please visit http://www.moorekuehn.com/practice/new-york-shareholder-derivative-litigation/

Attorney advertising. Prior results do not guarantee similar outcomes.

Moore Kuehn, PLLC
Fletcher Moore, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
[email protected] 
(212) 709-8245

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/moore-kuehn-pllc-encourages-investors-of-vygr-tile-or-swi-to-contact-law-firm-301218241.html

SOURCE Moore Kuehn, PLLC

Posted on

Cubic and LA Metro Release Contactless Fare Payment Option on Android

Cubic and LA Metro Release Contactless Fare Payment Option on Android

Metro riders can now “tap and ride” with the TAP app on Android

SAN DIEGO–(BUSINESS WIRE)–Cubic Corporation (NYSE:CUB) today announced its Cubic Transportation Systems (CTS) business division and the Los Angeles County Metropolitan Transportation Authority (Metro) launched the regional TAP application for Android phones, delivering a safe, contactless way to pay transit fare on Metro and 25 additional TAP transit agencies in L.A. County.

Cubic and Metro produced the state-of-the-art mobile application, which brings together virtual fare payment, TAP card management, trip-finding, multimodal program information and more, in one easy-to-use app.

“Cubic’s partnership with Metro has been a collaborative effort to continually deliver innovative solutions that simplify journeys for Metro riders,” said Jeff Lowinger, president of Cubic Transportation Systems. “The TAP app on Android ensures a safer, more convenient way to travel on Metro. Riders now have a TAP vending machine on their Android device and their entire account and journey can be managed from their device.”

By adding the TAP app on an Android device, riders can “tap and ride”, holding their device near the TAP validator upon boarding a bus or train and the fare is deducted immediately. The TAP app allows users to manage their TAP accounts and various multi-modal programs, such as Metro Bike Share, in addition to planning their journeys with a regional trip planner.

This Android release follows the iPhone and Apple Watch launch last September. For more information, visit taptogo.net.

About Cubic Corporation

Cubic is a technology-driven, market-leading provider of integrated solutions that increase situational understanding for transportation, defense C4ISR, and training customers worldwide to decrease urban congestion and improve the militaries’ effectiveness and operational readiness. Our teams innovate to make a positive difference in people’s lives. We simplify their daily journeys. We promote mission success and safety for those who serve their nation. For more information about Cubic, please visit www.cubic.com or on Twitter @CubicCorp.

Lauren Jochum

Cubic Transportation Systems

865-466-3860

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Other Transport Public Transport Technology Mobile/Wireless Rail Transport Other Travel Transportation Travel

MEDIA:

Logo
Logo
Posted on

American Cannabis Company, Inc. Talks to The Stock Day Podcast About Its 2021 Acquisition Strategy 

DENVER, CO, Jan. 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — The Stock Day Podcast welcomed American Cannabis Company, Inc. (OTCQB: AMMJ) (“the Company”), a company that offers end-to-end solutions to existing and aspiring participants in the cannabis and hemp industries. CEO of the Company, Terry Buffalo, joined Stock Day host Everett Jolly.

Jolly commented on the Company’s impressive growth over the last year, and asked about their background and current projects. “American Cannabis Company has been around since 2013,” shared Buffalo. “The company has built out over 2 million square feet of growth space, and along the way we have been looking to add additional products and services, which we have with SoHum Living Soils®,” he continued. “We’re currently looking to make these acquisitions and we’re happy to be able to diversify our income, and hopefully level our income, by adding these acquisitions to our portfolio.”

Jolly then asked about the Company’s recent announcement detailing a non-binding Letter of Intent (LOI) to purchase assets of Good Meds and BOSM Labs, a cannabis cultivation and extraction facility operating in a 60,000 sq. ft. building. “We have started the due diligence and the audit process is underway, and we’re looking to close this acquisition hopefully in the second quarter of this year,” said Buffalo. “It provides us the opportunity to expand up to 60,000 sq. ft. to help meet the growing medical and adult demand in the Colorado market.”

The conversation then turned to BOSM Labs, which produces live resin, live batter, budder, and shatter. “One of the big advantages of BOSM is that it is a hydrocarbon extraction lab. So, that will provide us the ability to add new products, SKUs, and meet the ever-growing demand here in the Colorado market.”

“What do you think will be some of the catalysts you will try to get done in the next two to three quarters?” asked Jolly. “The biggest thing is to get these two acquisitions that we have on the schedule for 2021, get them integrated into the company, and then start looking for 2022 opportunities,” said Buffalo.

Buffalo then elaborated on the Company’s consulting services division. “We’ve seen a big increase in calls and emails into the company. We have new clients now in all five states, and we are currently looking to add a few more in each one of those five states,” said Buffalo. “We’re looking for additional states to potentially come onboard before the end of the year, which will hopefully increase our consulting business for 2021.”

To close the interview, Buffalo shared that the Company will continue to be strategic in their acquisitions with a strong focus on building shareholder value. “We’re not just looking at top-line numbers, we’re looking to see how we can have profit,” said Buffalo. “That is our goal and I appreciate our shareholders being patient,” he added. “We’re working every day to bring value and provide a much cleaner type of product for the consumer than what is out there right now. Cleaner and greener is always the standard.”

To hear Terry Buffalo’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/7784397-american-cannabis-company-inc-discusses-its-2021-acquisition-strategy-with-the-stock-day-podcast

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

About American Cannabis Company, Inc.

American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis and hemp industries. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and operational best practices. We are continuing to grow the Company by promoting our operational management services, and license the American Cannabis Company brand, as well as continuing to analyze acquisition opportunities worldwide. American Cannabis Company also developed and owns a portfolio of branded products including: SoHum Living Soils® – Winner of the High Times S.T.A.S.H Award for “Best Potting Mix”, The Cultivation Cube™ and the High-Density Cultivation System™. We also design and provide other industry specific custom product solutions.

For more information about American Cannabis Company, please visit:
www.theacclife.com
www.americancannabisconsulting.com
www.americancannabiscompanyinc.com
www.sohumsoils.com
www.americanhempservices.com

For more information on Good Meds, please visit:
https://www.goodmeds.com/

For more information on BOSM Labs, please visit:
https://www.goodmeds.com/bosm-labs/

Video Links:
https://americancannabisconsulting.com/resources/video/ (ACC Site)
https://www.youtube.com/watch?v=aENC4aeNZis (High Density Cultivation System)
https://www.youtube.com/watch?v=e9rNxFph_tQ&t (Cultivation Cube)
https://www.youtube.com/watch?v=XoIcopO2yE8&t (SoHum Living Soils®)

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Cannabis Remains an Illegal Schedule 1 Drug Under Federal Law

Cannabis and its derivatives are considered illegal “Schedule 1” drugs under the Controlled Substances Act (21 U.S.C. § 811). As such, Cannabis and its derivatives are viewed as being highly addictive and having no medical value. The United States Drug Enforcement Agency enforces the Controlled Substances Act, and persons violating it are subject to federal criminal prosecution. The criminal penalty structure in the Controlled Substances Act is determined based on the specific predicate violations, including but not limited to: simple possession, drug trafficking, attempt and conspiracy, distribution to minors, trafficking in drug paraphernalia, money laundering, racketeering, environmental damage from illegal manufacturing, continuing criminal enterprise, and smuggling. A first conviction under the Controlled Substances Act can generally result in possible fines from $250,000 to $50 million dollars, and incarceration for periods generally from five and up to forty years. For a second conviction, fines increase generally from $500,000 to $75 million dollars, and incarceration for periods generally from ten years to twenty years to life.

Contact:

[email protected]
303-974-4770

About The “Stock Day” Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.



Posted on

Climate Real Impact Solutions II Acquisition Corporation Closes Its Public Offering

Climate Real Impact Solutions II Acquisition Corporation Closes Its Public Offering

Clean energy veterans launch second climate-focused SPAC to advance decarbonization solutions for the home, office and road

NEW YORK–(BUSINESS WIRE)–
Climate Real Impact Solutions II Acquisition Corporation (CRIS II) today announced the closing of its initial public offering of 24,150,000 units at a price of $10.00 per unit, including 3,150,000 units sold to the underwriters pursuant to the full exercise of the over-allotment option. CRIS II is the second climate-focused special-purpose acquisition company (SPAC) launched by a veteran team of founders and directors with decades of leadership and operating experience in the utility, renewable energy, private equity and finance industries. The first, Climate Change Crisis Real Impact I Acquisition Corporation, dba Climate Real Impact Solutions (CRIS), announced on January 22, 2021 a definitive agreement for business combination with EVgo, the largest electric vehicle public fast charging network in the U.S.

CRIS II is co-sponsored by private funds affiliated with Pacific Investment Management Company LLC (PIMCO), which has more than $640 billion in sustainable investment assets under its management.

For its evaluation of transaction opportunities, CRIS II will employ a business acquisition strategy that utilizes both financial and environmental metrics to maximize the value and the climate impact of the combined company. As with CRIS, the team will concentrate on an acquisition target involved in decarbonization of consumers’ homes, offices and means of transportation. Focusing on these subsectors offers opportunities for accelerating value creation by climate technologies that have already demonstrated commercial effectiveness and economic viability.

The CRIS II founders and directors offer wide-ranging, industry-leading expertise and experience, with clean energy and financial leadership roles served at Fortune 500 companies, private equity and investment firms, and government regulatory and advisory groups.

CRIS II will retain the executive leadership team from CRIS, consisting of co-founder, chief executive officer and director David Crane, former CEO of NRG Energy, Inc.; co-founder and chief financial officer John Cavalier, former managing partner of Hudson Clean Energy Partners and global chairman/senior advisor of Credit Suisse’s Energy Group; and co-founder and chief commercial officer Beth Comstock, former Vice Chair of General Electric (GE).

Richard Kauffman, energy investor and former New York State Chairman of Energy and Finance with oversight of the New York Energy Research and Development Authority (NYSERDA) and Jamie Weinstein, managing director, portfolio manager and head of corporate special situations at PIMCO, who both serve as directors for CRIS, will also serve on the CRIS II board of directors, Kauffman as chairman. New board members for CRIS II include:

  • Tanuja Dehne, independent director, president and CEO of the Geraldine R. Dodge Foundation, and former Chief Administrative Officer and Chief of Staff of NRG Energy, Inc.
  • Dawn Lippert, independent director, founder and CEO of Elemental Excelerator, Inc., a global climate technology investor and non-profit impact organization, and member of the Executive Council for Clean Energy for President Biden
  • Ron Lumbra, independent director, partner in the Global CEO & Board of Directors Practice at worldwide leadership advisory firm Heidrick & Struggles International Incorporated

“Our generation sits at a critical crossroads for tackling the climate crisis, and the upswell of support from the public markets in the last year for climate solutions shows us the financial commitments to rise to this moment are lining up,” said David Crane, CRIS II CEO and founder. “Decarbonization represents trillions of dollars in opportunity over the coming years and requires sustained efforts by clean energy leaders to scale impactful, high-growth climate solutions. Having reached an agreement on a deal for our first SPAC last week, CRIS II is an immediate renewal of our team’s commitment to identifying the companies delivering these solutions and providing them with the access to capital and counsel needed to accelerate their growth and transform their respective contributions to fighting the climate crisis.”

Advisors

Barclays and BofA Securities acted as joint book-running managers for the offering. Academy Securities, Drexel Hamilton, Loop Capital Markets, R. Seelaus & Co., LLC, Roberts and Ryan and Siebert Williams Shank acted as co-managers. Ropes & Gray LLP served as counsel to CRIS II and Davis Polk & Wardwell LLP served as counsel to the underwriters.

About Climate Real Impact Solutions II

Climate Real Impact Solutions II Acquisition Corporation (CRIS II) (NYSE: CLIM.U) is a special-purpose acquisition company (SPAC) formed to identify and acquire a scalable company making significant contributions to the fight against the climate crisis. CRIS II is the second SPAC led by a seasoned operations and leadership team with decades of experience at the intersection of climate change and capitalism and includes veterans from NRG, Credit Suisse, General Electric and Green Mountain Power.

Isaac Steinmetz

Director of Media Relations

[email protected]

646-883-3655

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

SoCalGas Data Analytics Team Named Most Innovative in the U.S.

Utility Analytics Institute recognizes SoCalGas’ excellence in data analytics, which has saved millions of dollars for the company and its customers

PR Newswire

LOS ANGELES, Jan. 29, 2021 /PRNewswire/ — Southern California Gas Co. (SoCalGas) announced today that its data analytics work has been recognized as the most innovative among over 150 utilities across the U.S. and the world by the Utility Analytics Institute (UAI).  The UAI praised SoCalGas’ use of data analytics to increase safety, save money for its customers, improve customer service, help conserve energy, and cut greenhouse gas emissions.

“We are honored to have been recognized for this award,” said Gillian Wright, senior vice president and chief customer officer at SoCalGas. “The work our data analytics team does is innovative, progressive, forward-thinking and leads to solving the company’s most complex business challenges. All of this is in support of SoCalGas’ mission to become the cleanest, safest and most innovative energy company in America.”

“SoCalGas has made impressive contributions to data analytics within the utility industry,” said Gina Weber, managing director at UAI. “Each winner of the UAI Excellence Awards was selected from a pool of talented individuals, teams and organizations and we congratulation them on this well-deserved recognition.”

Increased energy conservation is among the many benefits of SoCalGas’ data analytics work. For example, the utility’s data analytics team developed a way to identify customers who were less likely to conserve energy during a winter cold snap, allowing the company to target those households with reminders of the tools and information available to help them manage their natural gas use. This initiative is now saving these targeted customers over 300,000 therms of energy every year, reducing the bills of as many as 100,000 customers and decreasing greenhouse gas emissions. These reductions are among the more than 36.5 million therms SoCalGas helped natural gas users conserve through energy efficiency last year—saving customers more than $64 million and reducing carbon emissions linked to climate change by nearly 193,000 metric tons, the equivalent of taking 42,000 cars off the road for a year.

SoCalGas is also using data analytics to increase the safety of its employees and customers, and the new safety challenges created by the Covid-19 pandemic provide one example: Since the pandemic began, data analytics have allowed pinpoint accuracy in predicting the number and location of customer service orders, allowing for highly effective inventory management of Personal Protective Equipment as well as appropriate staffing at the 75 facilities across SoCalGas’ 24,000 square mile service territory.  

The data analytics team is also working to keep employees safe by providing customer service technicians with data to help them avoid hazards. Each technician will soon be provided with notice of hazardous driving routes prone to accidents, Covid-19 case rates in various geographic areas, and reminders of special safety precautions and gear required for certain types of service calls.

Preventing damage to gas pipelines is another way SoCalGas is using data analytics to increase safety. The company gathers construction permit data to gauge increased potential of gas line damage due to excavation. Areas where more construction permits are issued now receive additional reminders to have gas pipeline areas marked prior to any construction digging, along with other gas safety information.

In another example, data analytics is allowing SoCalGas to drastically reduce vehicle trips to inspect gas meters, which both increases employee safety and reduces greenhouse gas emissions associated with driving. In-depth analysis of data from the company’s Advance Meter technology can now accurately identify faulty meters without physical inspections. Every year, almost 50,000 inspection trips are avoided, leading to about 370,000 fewer miles driven, and saving 180 metric tons in carbon dioxide emissions per year. 

The UAI is a global consortium of over 160 member utilities and provides support to the industry with the goal of advancing utility transformation through analytics and digital innovation. To win the award, SoCalGas’ Performance Management and Operational Strategy (PMOS) team underwent panel interviews and provided case studies to demonstrate the many innovative ways they have tackled complex business processes and problems across SoCalGas.

Recently, SoCalGas announced its mission to build the cleanest, safest, and most innovative energy company in North America. More information on SoCalGas’ mission and strategic priorities can be found at socalgas.com/mission.

About SoCalGas 
Headquartered in Los Angeles, SoCalGas® is the largest gas distribution utility in the United States. SoCalGas delivers affordable, reliable, clean and increasingly renewable gas service to 21.8 million customers across 24,000 square miles of Central and Southern California, where more than 90 percent of residents use natural gas for heating, hot water, cooking, drying clothes or other uses. Gas delivered through the company’s pipelines also plays a key role in providing electricity to Californians— about 45 percent of electric power generated in the state comes from gas-fired power plants.

SoCalGas’ mission is to build the cleanest, safest and most innovative energy company in America, delivering affordable and increasingly renewable energy to its customers. In support of that mission, SoCalGas is committed to replacing 20 percent of its traditional natural gas supply with renewable natural gas (RNG) by 2030. Renewable natural gas is made from waste created by dairy farms, landfills and wastewater treatment plants. SoCalGas is also committed to investing in its gas delivery infrastructure while keeping bills affordable for our customers. From 2015 through 2019, the company invested nearly $7 billion to upgrade and modernize its pipeline system to enhance safety and reliability. SoCalGas is a subsidiary of Sempra Energy (NYSE: SRE), an energy services holding company based in San Diego. For more information visit socalgas.com/newsroom or connect with SoCalGas on Twitter (@SoCalGas), Instagram (@SoCalGas) and Facebook.  

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/socalgas-data-analytics-team-named-most-innovative-in-the-us-301218231.html

SOURCE Southern California Gas Company

Posted on

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*

Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate

When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move closer to the goal of seizure reduction and seizure freedom

ZUG, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) — Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of cenobamate for the adjunctive treatment of focal onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic products.

The European Commission (EC), which is authorized to approve medicines in the European Union, is expected to issue its decision within 67 days of receipt of the CHMP opinion.

There are an estimated six million people in Europe with epilepsy1 and approximately 40% of adult people with epilepsy have inadequate control of seizures after treatment with two anti-seizure medications (ASMs).2

Mark Altmeyer, President and CEO, Arvelle Therapeutics, said,
“Despite the number of ASMs that are currently available, a large proportion of patients continue to have seizures which can have devastating effects on them and their families’ lives. Cenobamate has been shown to significantly improve seizure control for focal-onset seizures in adult patients and this positive CHMP opinion means that patients may soon have a new treatment option,” he added.

In January 2021, Angelini Pharma announced that they concluded a definitive merger agreement under which Angelini Pharma will acquire Arvelle Therapeutics. As a result, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom). Angelini plans to launch cenobamate after receiving approval from the EC which is expected by Q2 2021.

“Positive CHMP opinion of cenobamate represents an important milestone for Angelini Pharma and for patients. Cenobamate showed significant efficacy, with more patients achieving a 50% or greater reduction in seizure frequency and unprecedented rates of seizure freedom of up to 21% compared to placebo. We are impressed and excited about what Arvelle Therapeutics’ people have achieved and built since we share the same vision,” said Pierluigi Antonelli, CEO Angelini Pharma. “The acquisition of Arvelle Therapeutics will propel us into a leading European player, well positioned to address the needs of patients with different Central Nervous System (CNS) disorders through an innovative portfolio, medical capabilities and extensive commercial presence. The agreement will be completed in the first week of February.”

Cenobamate, which was discovered by SK Biopharmaceuticals, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of partial-onset (focal) seizures in adults, and it is commercially available in the U.S under the trademark XCOPRI® (cenobamate tablets) CV.

Dr. Jeong Woo Cho, CEO of SK Biopharmaceuticals, said, “The positive CHMP opinion brings us all toward achieving a major milestone that will enable patients in Europe to access cenobamate, which has been 20 years in the making, once approved, SK Biopharmaceuticals will ensure, with its European partners, a launch of this medicine to the epilepsy community.”

The CHMP positive opinion was based on three trials involving over 1,900 patients. The main trial (study 017) published in The Lancet Neurology3 was a multicentre, double-blind, randomized, placebo-controlled trial that demonstrated that cenobamate is an effective treatment option for adult patients with focal-onset seizures taking 1-3 ASMs.

Cenobamate demonstrated significantly higher responder rates (percentage of patients achieving ≥50% reduction in seizures frequency) across all doses during the 12-week maintenance phase compared to placebo. The ≥50% responder rates were 40% (p=0.036), 56% (p<0.001), and 64% (p<0.001), for the 100 mg/day, 200 mg/day, and 400 mg/day cenobamate groups, respectively, compared to 25% for placebo. Furthermore, 4% (not significant, p=0.369), 11% (p=0.002), and 21% (p<0.001), of patients treated with cenobamate 100 mg, 200 mg, and 400 mg, respectively, reported 100% reduction in seizure frequency (100% seizure freedom) compared with only 1% of placebo-treated patients during the maintenance phase.3

The global disease burden of epilepsy is high.4,5 A diagnosis of epilepsy may confer significant disability on the individual, including physical, psychological and social problems that could negatively impact self-esteem, family, relationships, leisure, work, career prospects and ability to drive.4,6

In addition, people with epilepsy whose seizures are poorly controlled have higher morbidity and mortality rates and often experience comorbid illnesses, social stigmatisation, psychological dysfunction and a reduced quality of life.7,8

*Cenobamate was recommended as adjunctive treatment of focal onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic products.

About Arvelle Therapeutics

Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational anti-seizure medicine, in the European market. Arvelle is headquartered in Switzerland and received start-up financing of $207.8 million, one of the largest initial financing commitments for a European-focused biopharmaceutical company, with investments from a global syndicate including NovaQuest Capital Management, BRV Capital Management, LSP, H.I.G. BioHealth Partners, Andera Partners, F-Prime Capital and KB Investments. More information is available at https://arvelletx.com.

About Angelini Pharma

Angelini Pharma is an international pharmaceutical company, part of the Italian privately-owned Angelini Group. Angelini Pharma is committed to helping patients in the therapeutic areas of Mental Health (including Pain), Rare Diseases and Consumer Healthcare. Over the past 50 years, in the field of mental health, Angelini Pharma has gained international recognition for its substantial efforts to improve the management of patients with mental health disorders thanks to important, internally developed, molecules (such as trazodone) and its commitment to fighting mental health stigma. Angelini Pharma operates directly in 15 countries employing almost 3,000 people and commercializes its products in more than 50 countries through strategic alliances with leading international pharmaceutical groups.

In January 2021, Angelini Pharma announced that they concluded a definitive merger agreement under which Angelini Pharma will acquire Arvelle Therapeutics. As a result, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom).

About SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on early research in oncology. For more information, visit SK Biopharmaceuticals’ website at www.skbp.com/eng and SK life science’s website at www.SKLifeScienceInc.com.

About Cenobamate
Cenobamate was discovered by SK Biopharmaceuticals and SK life science and is an FDA-approved ASM for the treatment of partial-onset seizures in adults (also known as focal-onset seizures). Cenobamate has been approved in the U.S. where it is commercially available under the trademark XCOPRI®.9  IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI® (cenobamate tablets) CV can be found on www.xcopri.com

Cenobamate is a novel small molecule that provides a unique, dual, complementary mechanism of action aimed at treatment of seizures.10,11,12 Cenobamate is the only anti-seizure medication which, at clinically relevant concentrations, acts both as a positive allosteric modulator of GABAA receptors at a non-benzodiazepine binding site and preferentially blocks the persistent sodium current.11,12 The unique dual mechanism of action of cenobamate suggests that it has the potential to both prevent seizure initiation and limit seizure spread.13,14,15,16,17

Long-term data of cenobamate is being studied in the open-label extensions of the double-blind placebo control trials as well as the open-label safety study in adults with uncontrolled focal-onset seizures.18 Additionally, cenobamate is being assessed in an ongoing randomized, double-blind, placebo-controlled trial evaluating its safety and efficacy as adjunctive therapy in patients with primary generalized tonic-clonic seizures (NCT03678753).19

Cenobamate has recently gained recognition by healthcare regulatory bodies in the United Kingdom and Germany given its potential use in treatment resistant focal-onset seizures in epilepsy. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has designated cenobamate as a Promising Innovative Medicine (PIM). A PIM designation is an early indication that a medicinal product is a promising candidate for the Early Access to Medicines Scheme.

In addition, as of August 2020, the German Federal Institute for Drugs and Medical Devices (BfArM) has included cenobamate for the treatment of drug-resistant focal-onset seizures in adults in its list of confirmed drugs for compassionate use (CPU) programmes for one year within the country.

About Study 017

3

Study 017 was a multicentre, double-blind, randomized, placebo-controlled, dose-response study to evaluate the safety and efficacy of cenobamate as an adjunctive therapy in adults (18 to 70 years old) with uncontrolled focal epilepsy despite treatment with 1-3 anti-epileptic drugs (AEDs).

Following an 8-week baseline period, the study participants were randomized to one of three doses of cenobamate (100 mg, 200 mg and 400 mg once daily) or placebo for 18 weeks (6-week titration phase and 12-week maintenance phase). The primary outcomes were median percentage seizure reduction over the entire study and ≥50% responder rate (percentage of patients achieving ≥50% reduction in seizures) during the maintenance phase. Patients who had the option to enrol in an open-label extension of the 017 study will provide additional insight into the long-term clinical efficacy and safety profile of adjunctive cenobamate.

References

1. Epilepsy Alliance Europe. Background information. https://www.epilepsyallianceeurope.org/about/background/ Last accessed 03.12.2020.
2. Chen Z et al. JAMA Neurol. 2018 Mar 1;75(3):279-286.
3. Krauss GL et al. Lancet Neurol. 2020 Apr;19(4):288-289.
4. Epilepsy: a public health imperative. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
5. ILAE/IBE/WHO. Global Campaign Against Epilepsy: Out of the Shadows. 2003.
6. Kaiser S, et al. Seizure. 2002;11:356–360.
7. Engel J. Neurol. 2003;60(9):1412.
8. Engel J. Ann Indian Acad Neurol. 2014;17(Suppl 1):S12–7.
9. Cenobamate prescribing information. FDA. Last accessed 20 July, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf 
10. Guignet M, Campbell A, White HS, Epilepsia. 2020 Oct 16. doi: 10.1111/epi.16718. Online ahead of print
11. Nakamura M, et al. Eur J Pharmacol 2019;855:175-182.
12. Sharma R, et al. Eur J Pharmacol 2020;879:173117.
13. Anderson LL et al., Epilepsia 2014; 55(8):1274-1283.
14. Piredda SG et al, J Pharmacol Exp Ther. 1985;232(3):741-745.
15. Stafstrom CE, Epilepsy Curr 2007; 7(1):15-22.
16. Vreugdenhil M et al., Eur J Neurosci., 2004; 19: 2769-2778.
17. White HS et al, Epilepsy Res. 1997;28(3):167-79.
18. Sperling MR, et al. Epilepsia, Feb 2020;61:1099–1108.
19. Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures NCT03678753.



For more information, please contact:

Arvelle Therapeutics
Juan Vergez
Head of Marketing and Corporate Communications
Email: [email protected]

Angelini Pharma
Daniela Poggio
Head of Communications
Email: [email protected]

SK Biopharmaceuticals
Hyongki Park
Head of Communications
Email: [email protected]

Trio Health
Nina Bass  +44 (0) 208 8080 3005
[email protected]

Chloe Nichols  +44 (0) 208 8080 3004
[email protected]

Nick James  +44 (0) 208 8080 3006
[email protected]